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Abstract
Background: The AGE-RAGE-oxidative stress (AROS) axis is involved in the onset and progression of metabolic
syndrome induced by a high-fructose diet (HFD). PPARγ activation is known to modulate metabolic syndrome;
however a systems-level investigation looking at the protective effects of PPARγ activation as related to the AROS
axis has not been performed.
The aim of this work is to simultaneously characterize multiple molecular parameters within the AROS axis, using
samples taken from different body fluids and tissues of a rat model of HFD-induced metabolic syndrome, in the
presence or absence of a PPARγ agonist, Rosiglitazone (RGZ).
Methods: Rats were fed with 60% HFD for the first half of the treatment duration (21 days) then continued with
either HFD alone or HFD plus RGZ for the second half.
Results: Rats receiving HFD alone showed metabolic syndrome manifestations including hypertension, dyslipidemia,
increased glucose levels and insulin resistance, as well as abnormal kidney and inflammatory parameters. Systolic blood
pressure, plasma triglyceride and glucose levels, plasma creatinine, and albuminuria were significantly improved in the
presence of RGZ. The following molecular parameters of the AROS axis were significantly upregulated in our rat model:
carboxymethyl lysine (CML) in urine and liver; carboxyethyl lysine (CEL) in urine; advanced glycation end products
(AGEs) in plasma; receptor for advanced glycation end products (RAGE) in liver and kidney; advanced oxidation protein
products (AOPP) in plasma; and 4-hydroxynonenal (HNE) in plasma, liver, and kidney. Conversely, with RGZ
administration, the upregulation of AOPP and AGEs in plasma, CML and CEL in urine, RAGE in liver as well as
HNE in plasma and liver was significantly counteracted/prevented.
Conclusions: Our data demonstrate (i) the systems-level regulatory landscape of HFD-induced metabolic
syndrome involving multiple molecular parameters, including HNE, AGEs and their receptor RAGE, and (ii)
attenuation of metabolic syndrome by PPARγ modulation.
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Background
Chronic non-communicable diseases such as diabetes,
heart disease and cancer are responsible for 35 million
deaths annually [1]. Many of these diseases are frequently
associated with a complex disorder called metabolic syn-
drome, which is characterized by a group of co-occurring
conditions (though not necessarily all occurring in the
same patient): abdominal obesity, increased blood
pressure, increased glucose level and multiple dyslipidae-
mias [2]; insulin resistance is also frequently found to
occur in a subset of patients exibiting this syndrome [3].
These factors are typically associated with an increased
risk of developing cardiovascular disease, type 2 diabetes
mellitus and renal disease [1, 3, 4]. Both the underlying
pathogenic mechanisms, as well as specific diagnostic cri-
teria for metabolic syndrome remain incompletely defined,
but this syndrome is known to be strongly related to con-
sumption of high levels of fructose [1, 3, 4]. Most of the
studies on the pathogenesis of metabolic syndrome have
focused on advanced stages of the disorder. Recently, non-
enzymatic protein glycation and lipoxidation have
emerged as major candidates for initiating and sustaining
this syndrome [4].
Fructose and the corresponding metabolic oxidation
by-products such as methylglyoxal (MGO) react non-
enzymatically with nucleophilic substrates such as proteins,
forming adducts called advanced glycation end-products
(AGEs) [5]. Among the numerous AGEs produced in vivo,
two specific products, carboxymethyl lysine (CML) [6] and
carboxyethyl lysine (CEL) [7], are especially abundant.
AGEs interact with their specific cell-surface receptor,
RAGE, initiating a signalling cascade that activates the
transcription factor nuclear factor-kappa B (NF-κB), lead-
ing to increased release of inflammatory cytokines such as
TNF-α [8]. The resulting increase in inflammation con-
tributes to cellular dysfunction and tissue destruction.
Moreover AGEs down-regulate intracellular detoxifying
mechanisms. The result is the intensification of conditions
such as diabetes [8].
This AGE-RAGE axis, activating NADPH oxidases and/
or by other analogous mechanisms, also induces the for-
mation of reactive oxygen species (ROS), which further in-
crease cellular oxidative damage [8]. Advanced lipoxidation
end-products (ALEs), including 4-hydroxynonenal (HNE),
an α,β-unsaturated hydroxyalkenal, are formed by a mech-
anism involving lipid peroxidation; these reactive species
can subsequently form adducts with proteins, often result-
ing in protein dysfunction. Accumulating evidence shows
that a high-fructose diet (HFD) can also increase HNE pro-
duction through activation of the AGE-RAGE-oxidative
stress (AROS) axis [9–13]. Despite the increasing number
of studies, the exact role of the AROS axis in the pathogen-
esis and progression of metabolic syndrome is still not
completely understood. Importantly, these previous studies
also have not evaluated all of the relevant parameters
affecting production of AGEs and ALEs simutanuously,
within a single model system.
A promising approach for both studying and treating
metabolic syndrome involves the use of a class of drugs
called thiazolidinediones [14–17], previously used to treat
diabetes. Rosiglitazone (RGZ), the prototypical drug in this
class, activates the nuclear peroxisome proliferator-
activated receptor γ (PPARγ), a type II nuclear receptor,
which in turn alters the expression of numerous genes
[18], ultimately resulting in reduced blood concentrations
of glucose, fatty acids, and insulin [19]. RGZ has also been
shown to reduce the accumulation of AGEs [20–25], but
little is known about the possible influence of RGZ on
levels of the lipid peroxidation product, HNE.
Although there is no single known effective drug treat-
ment for all the components of metabolic syndrome
[26], there is a strong interest in developing (i) new mol-
ecules that maintain and extend RGZ therapeutic effects
without its toxic side effects, and (ii) drugs specifically
targeting the PPARγ receptor to benefit multiple
diseases or co-occurring conditions in metabolic
syndrome [27–30]. The specific aim of this study was to
apply a systems biology approach for comprehensive
evaluation of the multiple molecular modifications tak-
ing place via stimulation of the AROS axis, both without
and with agonist potentiation of PPARγ activity by RGZ.
The results provide a more complete picture of the land-
scape of the AROS axis, and illustrate the potential value
of a systems approach in evaluating new drug candidates




The control diet contained 60% corn starch (carbohy-
drates), 20% casein (protein), 0.3% methionine, 5% lard
(fat), 8% cellulose, 5% mineral mixture, 1% vitamin mix-
ture, and zinc carbonate 0.004%. The fructose diet
contained all the ingredients except corn starch, which
was replaced by an equal quantity of fructose. Both diets
were in pellet form. The diets were supplied by Diete
Speciali, Mucedola s.r.l., Italy.
Animals
Fifteen male Sprague-Dawley rats (Harlan Laboratories
Inc., San Pietro al Natisone, Udine, Italy) weighing 200
± 20 g (8 weeks of age) were studied. Rats were housed
under constant environmental conditions (22 ± 1 °C,
50 ± 5% relative humidity, 12-h light/12-h dark cycle),
with standard laboratory rat chow (batch 221644) or
60% high fructose diet (batch 221643) obtained from
Mucedola s.r.l., Settimo Milanese, Milan, Italy and tap
water ad libitum. Animals were acclimatized for a
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period of at least seven days before the use. The study
was approved (protocol n° 16/2010) by the Animal
Ethics Committee of University of Milan, Italy and
communicated to the Italian Ministry of Health, having
regard to the article seven of the D.L. 116/92. In addition,
the study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85–23, revised
1996). All efforts were made to minimize animal suffering.
Urine, plasma and tissue sampling
At the end of the experiment, rats within each group
were placed in individual metabolic cages (#3600 M021;
Tecniplast S.p.A, Buguggiate, Varese, Italy) for urine col-
lections while continuing to have access to food and
water. After a 24 h acclimation period, urine sam-
ples were collected for a 24 h period, and then the ani-
mals were returned to their usual cages. During the 24 h
period spent in the metabolic cage, the animals did not
receive RGZ. One ml of a 360 mM BHT ethanolic solu-
tion was added to the urine conical collection tubes
(maintained at 4 °C), and 5 ml aliquots were frozen
and stored at -80 °C until analysis.
At the end of the experiment, blood samples were col-
lected from the tail vein in heparinized capillary tubes.
Rats were anaesthetized with 60 mg/kg i.p. thiopentone
sodium (Abbott s.r.l, Roma, Italy) and blood was col-
lected from the inferior cava vein. Blood samples were
centrifuged for 15 min. (2000 g at 4 °C), and plasma
samples (500 μl aliquots) stored at -80 °C until analysis.
The animals were then killed by decapitation for kidney
and liver harvesting. The harvested organs were imme-
diately frozen in liquid nitrogen, and stored at -80 °C
until assayed. Just before analysis, tissue samples were
thawed, rinsed in ice-cold physiological saline, weighed
and minced [31].
Indirect systolic blood pressure (SBP) and heart rate
measurements
At the end of the experiment, SBP was measured in con-
scious rats by tail-cuff plethysmography [32]. The animals
where pre-warmed at 37 °C for 30 min., and the measure-
ments were obtained with the rats restrained in a plastic
chamber without anaesthesia. A pneumatic pulse trans-
ducer positioned on the ventral surface of the tail distal to
the occlusion cuff detected the return of the pulse after a
slow deflation of the cuff. Cuff pressure was determined by
a pneumatic pulse transducer with a programmed electro-
sphygmomanometer (mod 58500; Ugo Basile, Comerio,
Varese, Italy). SBP values for individual rats were obtained
from the average of three consecutive measurements and
were considered valid only when these readings did not
differ by more than 5 mmHg. At the same time, heart rate
was measured from the arterial pulse wave.
Experimental design
At the beginning of our study, rats were randomly di-
vided into three groups. One group was maintained on
standard rat chow diet for six weeks (CTR group),
whereas the other two groups were given fructose-
enriched diet for six weeks. For the two groups that
received fructose-enriched diet, one group was also
given Rosiglitazone (10 mg ⁄ kg ⁄ day, in powder form;
Glaxo-Smith-Klein, Middlesex, UK) three weeks after
the initiation of the diet (RGZ group) and the other one
was continued with fructose-enriched diet alone (HFD
group). RGZ was orally administered by gastric gavage
to rats during the last three weeks of the study. The
compound were dissolved in a 5% (v/v) DMSO/H2O so-
lution and diluted with 1% PEG400 (v/v) distilled H2O
solution and kept protected from light throughout the
study. During all the experiments, rats had free access to
water and food. The rats were placed in metabolic cages
(Tecniplast S.p.A., Buguggiate, Italy).
Blood and urine biochemistry
Plasma TNF-α and IL-6 were determined by ELISA
using a commercially available kit (R&D Systems, Inc.,
USA) according to the manufacturer’s instructions.
Advanced oxidation protein products (AOPP) were
quantified according to the method previously described
by Witko-Sarsat et al.[33].
Plasma and urinary fluorescent AGEs were determined
by using a spectrofluorimeter (Perkin Elmer LS50B)
setting the excitation wavelength at 370 nm and emis-
sion at 440 nm. AGE values were expressed as fluores-
cence units (FU)/ml for plasma samples and in 24 h for
urines.
Plasma and urine carboxymethyl lysine (CML),
carboxyethyl lysine (CEL) levels were measured by the
use of commercially available kit: ELISA kit (OxiSelect™
CML ELISA Kit, Cell Biolabs Inc., OxiSelect™ CEL
ELISA Kit, Cell Biolabs Inc.). Plasma and urine were di-
luted and tested in duplicate. The assay was performed
according to the manufacturer’s instructions. Absorb-
ance was read on a microplate reader: Wallac Vic-
tor 2 Wallac 1420 workstation.
Surrogate indices of steatosis and/or parameters of
impaired fat metabolism
Aspartate aminotransferase (AST), alanine transaminase
(ALT), hepatic total lipids, hepatic triglycerides and
hepatic total cholesterol were measured as previously
described [34].
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Preparation of lysate from tissues
Tissues were dissected with clean tools, on ice, as
quickly as possible to prevent degradation by proteases.
The tissues pieces were placed in round-glass tubes.
Lysis buffer (20 mM Tris-HCl, pH 7.5, 0.1% SDS, 1%
Triton X-100, 1 mM Na2EDTA, 1% Protease inhibitors
cocktail) without beta-mercaptoethanol was added in
proportion 1: 2 (w/v) to the small pieces of tissues and
put on ice. Homogenization was performed using an
Ultra Turrax T25 (Janke & Kunkel, IKA Labortechnik).
2-Mercaptoethanol was added, samples were sonicated
and centrifuged for 20 min at 13,000 g at 4 °C in a
microcentrifuge MIKRO 120 HETTICH zentrifugen).
The Triton X-100-soluble supernatant fraction (Sup)
was removed, the Bradford protein assay was performed
and the samples were stored at -80 °C.
Laemmli buffer (4X) was added to the Triton X-100-
insoluble fraction (Pellet) (which enriches for detergent-
resistant membranes, such as lipid rafts) at the bottom
of the tubes (1:1, v/v), incubated 20 min at 95 °C, and
centrifuged at 13,000 g, 5 min. The protein assay was
then performed on the solublized Pellet fraction before
storing the samples at -80 °C.
Preparation of samples and SDS-PAGE
For Sup fractions, Laemmli Buffer 2X with beta-
mercaptoethanol was added to samples 1:1(v/v), and
heated for 5 min in Thermobloc FALC. One part of the
sample was further diluted with two parts of Laemmli buf-
fer with beta-mercaptoethanol and centrifuged 3 min.
20 μg of proteins were loaded on Any kD™ Mini-
PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) for
SDS-PAGE. For Pellet fractions, each sample was heated
for 5 min, taken one part and added to nine parts of
Laemmli Buffer and centrifuged 3 min. 20 μg of proteins
were loaded for SDS-PAGE. Precision Plus Protein™ Wes-
ternC Standards, Bio-Safe Coomassie Stain, 10x Tris/Gly-
cine/SDS, Bio-Safe Coomassie Stain purchased from Bio-
Rad were used to perform SDS PAGE.
Spectrophotometric measurements for protein assay
were carried out with a computer-aided PerkinElmer
UV/Vis Lambda 16 spectrophotometer.
Detection and densitometric quantification of CML, HNE,
RAGE content
Rabbit Anti-CML Antibody and Rabbit Anti-HNE poly-
clonal antibody were obtained from Cell Biolabs, Anti-
beta actin Goat Anti-Mouse IgG, HRP-conjugate from
Ambion (Life Technologies), Goat anti-RAGE (N-16)
polyclonal antibody from Santa Cruz Biotechnology
(Santa Cruz, CA). The homogenates were resolved by
SDS-PAGE followed by electrophoretic gel transfer to
Trans-Blot Transfer Pack, 0.2 μm nitrocellulose mem-
brane (Bio-Rad) with a Trans Blot Turbo (Bio-Rad).
Electrotransfer was carried out at 25 limit V, 2.5 con-
stant A for 7 min and Ponceau staining (0.1% Ponceau S
(w/v) in 5% acetic acid) was performed.
The blots were incubated in immunoblotting buffer
(TBST: 20 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 0.05%
Tween-20) (Bio-Rad) containing 5% (w/v) Skim Milk
Powder at room temperature, followed by washing with
TBST. Blots were then incubated overnight at 4 °C with
either anti-CML antibodies (1:800) in TBST containing
5% milk, or Anti-HNE polyclonal antibody (1:800) or
anti-RAGE antibodies (1:400) both in TBST containing
3% milk. The blots were washed three times with TBST,
then incubated in Goat Anti-Rabbit IgG, HRP (horserad-
ish peroxidase)-conjugate (Jackson Immune Research)
1:10000 in TBST, in the case of CML, or with Goat anti-
rabbit IgG (H + L) IgG (Invitrogen) 1:1000 in TBST con-
taining 3% milk, in the case of HNE and Rabbit Anti-
Goat IgG, HRP-conjugate (Sigma) 1:50000 in TBST, in
the case of RAGE. After washing the blots with TBST,
CML and HNE modified proteins or RAGE were visual-
ized with Immun-Star WesternC Chemiluminescent Kit
(BioRad).
After washing with TBST, the blots were blocked and
probed in the same manner as stated above. Anti-beta
actin, freshly diluted 1:10000 in TBST containing 3%
nonfat dry milk, was used as primary antibody and goat
anti-mouse IgG1(gamma1) HRP (Invitrogen) was used
as the secondary antibody.
All immunoblot images were scanned by ChemiDoc
MP (Bio-Rad) and densitometric quantifications were
performed using Image Lab software (Bio-Rad). Total
CML and HNE were quantified using the intensity of
the whole lane, whereas RAGE protein expression was
quantified using only the intensity of the stained bands.
Beta-actin intensity was used to normalize CML, HNE
or RAGE intensity.
Liver and kidney histology
Liver and renal histology was performed on formalin
fixed and paraffin-embedded tissues. Four-micrometer
kidney sections were stained with hematoxylin and
eosin, PAS (periodic acid-Schiff ) and Masson trichrome;
liver sections with hematoxylin and eosin and Masson
trichrome. Kidneys specimens were evaluated for glo-
merulosclerosis, tubulointerstitial injury, and interstitial
fibrosis, as previously reported [31]. Liver slides were
assessed for steatosis, inflammation and fibrosis, using
the NAFLD activity score (NAS) [35].
Data analysis
Data are reported as means ± SEM for three independent
experiments performed in duplicate. ANOVA followed
by the Newman Keuls multiple comparison test was
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used to compare the data. A 0.05 level of probability was
set as the minimum criterion of significance.
The statistical analysis was performed using the
Prism6 software package (Graphpad Software, San
Diego, CA, USA).
Principal component analysis (PCA) of plasma levels
of glucose tryglycerides, creatinine, insulin, TNF-α, IL-6
and total cholesterol, urine albumin levels, systolic blood
pressure, and body weight gain data was performed
using R package “pca3d”: Three Dimensional PCA Plots.
R package version 0.8. https://CRAN.R-project.org/
package=pca3d
Results
Experimental model of metabolic syndrome
In accordance with the currently accepted clinical defin-
ition of metabolic syndrome in humans [2], a model of
metabolic syndrome (employing a high-fructose diet;
HFD) was developed in rats which exhibited the
presence of 3 out of the 5 established criteria: (i) hyper-
tension, (ii) high levels of triglycerides, and (iii) increased
plasma glucose (Fig. 1a-c, HFD group [middle bars]
compared with control group [left bars]). For the
remaining two criteria, one (increased body weight) was
not significantly changed in this model (Fig. 1d), and the
other (decreased HDL cholesterol level) was not mea-
sured. Several additional conditions often accompanying
the syndrome were also present: insulin resistance (in-
creased plasma insulin) (Fig. 1e), kidney damage (in-
creased plasma creatinine and albuminuria) (Fig. 1f-g)
and inflammation (increased plasma levels of TNF-α
and interleukin six (IL-6)) (Fig. 1h-i).
No steatosis or fibrosis was observed in the liver in
response to the HFD (Additional file 1: Figure S1 A,
B), even though several biochemical surrogate indices
of impaired liver fat metabolism were present (includ-
ing increased levels of AST [36, 37], hepatic total
lipids [38], hepatic triglycerides [39] and hepatic total
Fig. 1 Effect of HFD on established criteria and associated parameters of metabolic syndrome, in the absence and presence of RGZ. Established
criteria for metabolic syndrome that were evaluated included: (a) systolic blood pressure, (b) plasma triglycerides and (c) plasma glucose. Several
additional parameters often associated with the syndrome were also evaluated: (d) body weight, (e) plasma insulin, (f-g) kidney damage and
(h-i) inflammatory cytokine response. Data are mean ± SEM * P < 0.05; **P < 0.01; *** P < 0.001
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cholesterol [40] (Additional file 2: Figure S2)). Simi-
larly, no morphological evidence of renal damage was
detected, such as glomerulosclerosis, interstitial in-
flammatory cell infiltrates, tubular dilatation and/or
atrophy and interstitial fibrosis (Additional file 1: Fig-
ure S1 D, E). However, albuminuria and increased
plasma creatinine levels were found, suggesting some
degree of renal injury (Fig. 1f, g).
PPARγ agonist attenuation of metabolic syndrome
Following three weeks of HFD, addition of RGZ while
continuing HFD for the remaining three weeks re-
duced some physiological parameters of metabolic
syndrome in our model: systolic blood pressure, and
the levels of both triglycerides and glucose (Fig. 1a-c,
HFD group [middle bars] compared with RGZ group
[right bars]). RGZ also provided a protective effect
from kidney damage as shown by the normalization of
plasma creatinine and albumin levels compared with
control values (Fig. 1f-g). In contrast, the plasma levels
of insulin as well as those of inflammatory markers,
were not significantly attenuated by RGZ (Fig. 1e, h, i).
Principle component analysis (PCA) was employed
to identify relationship patterns among animals in the
three treatment groups (control, HFD, HFD + RGZ)
for the multidimentional datasets (i.e., the collection
of measured parameters for metabolic syndrome and
associated conditions; see Methods for parameter
list). The resulting PCA analysis showed that animals
from each treatment group were clearly clustered to-
gether, and that each group was separated from
Fig. 2 Principal component analysis of results from the three treatment groups (control, HFD, HFD + RGZ) for the multidimentional datasets.
Principal component analysis (PCA) was performed for plasma levels of glucose, tryglycerides, creatinine, insulin, TNF-α, IL-6 and total cholesterol,
urine albumin levels, systolic blood pressure, and body weight gain data. Results showed that each treatment group clustered separately from
the others and that the RGZ group was located between the control and HFD groups
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the other two (Fig. 2). The HFD group was widely sepa-
rated from the control group, while the RGZ group was
located intermediate between the other two groups, in
agreement with the overall picture that emerged from
the data shown in Fig. 1, namely that HFD induced
metabolic syndrome and RGZ significantly attenuated
the pathological conditions.
Moreover, the increases in the levels of hepatic triglyc-
erides and hepatic total cholesterol were also prevented
by RGZ treatment (Additional file 2: Figure S2D, E), but
RGZ did not prevent the increase in levels of AST and
hepatic total lipids (Additional file 2: Figure S2A, F).
Systems biology approach to investigate the AROS axis
and lipoxidative protein modifications
We next applied a comprehensive systems biology
approach to investigate the complex molecular changes
during HFD-induced metabolic syndrome that could be
mediated by glycoxidative and lipoxidative protein modi-
fications. We quantified multiple oxidative protein modi-
fications in plasma, urine, kidney and liver, including the
levels of AOPP, total AGEs, specific AGEs (CML, CEL)
and HNE-protein adducts, as well as RAGE.
Oxidative damage markers and glycation products in
plasma and urine
Oxidative damage to proteins in plasma from the HFD
group (as detected by AOPP) was significantly increased
(>2-fold) and completely prevented by RGZ; in fact,
RGZ significantly suppressed AOPP levels below those
of control animals (Fig. 3a, HFD group [middle bars]
compared with RGZ group [right bars]). HFD also in-
creased the levels of total AGEs in plasma, while the
levels of these toxic products were maintained at control
levels by RGZ (Fig. 3b). Interestingly, levels of two spe-
cific AGEs, CML and CEL, in plasma were not altered
by either HFD or RGZ (Fig. 3c, d). In urine, the level of
total AGEs was not changed (Fig. 3e), but both CML
and CEL exibited > 2-fold increases in response to HFD
and a counteracting effect from RGZ (Fig. 3f, g).
Glycation and RAGE expression in kidney and liver
Kidney and liver tissues lysates were separated into a
Triton X-100 soluble fraction (Sup) (representing essen-
tially a total cell lysate) and a Triton X-100 insoluble
fraction (Pellet), which enriches for specific detergent
resistant membranes (e.g., lipid rafts) [41]. This frac-
tionation scheme was important because the receptor
Fig. 3 Oxidative damage in plasma and urine. Levels of oxidative stress markers were measured in plasma and urine in response to HFD in the
absence and presence of RGZ. a plasma AOPP; (b) plasma total AGEs; (c) plasma CML; (d) plasma CEL; (e) urine total AGEs; (f) urine CML and (g)
urine CEL. Data are mean ± SEM * P < 0.05; **P < 0.01; *** P < 0.001
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for AGEs (RAGE) is localized in two membrane com-
partments: (i) the plasma membrane (Triton X-100
soluble “Sup” fraction, in which RAGE signalling is in-
active), and (ii) lipid rafts (where active RAGE signal-
ling occurs) [42, 43].
First, the level of glycation (CML) was increased al-
most 2-fold in the Sup fraction of the liver from the
HFD group (Fig. 4b, control group [left bars] compared
with HFD group [middle bars]). At this stage of the
syndrome, we did not detect any other significant
change in the levels of CML, including in the Pellet
fraction from liver (Fig. 4d) nor in either fraction from
kidney (Fig. 4a, c). RGZ had no effect on the levels of
CML in either liver or kidney (Fig. 4a-d).
No statistically significant increase in RAGE levels
were detected in the kidney in response to HFD, and no
significant attenuation was induced by RGZ treatment
(Fig. 5a, c). Similarly, no change in levels of inactive
RAGE (Sup fraction) in liver resulted from HFD (Fig. 5b).
In contrast, HFD induced a dramatic 4-fold increase in
levels of active RAGE (Pellet fraction) in liver (Fig. 5d).
Furthermore, in liver, RGZ treatment resulted in signifi-
cantly decreased levels of inactive RAGE (Sup fraction)
(to 50% of control levels) and normalization of levels of
active RAGE (Pellet fraction) (Fig. 5b, d).
Lipoxidation in plasma, kidney and liver
The level of HNE-modified proteins in plasma was in-
creased almost 2-fold by HFD treatment, while RGZ
completely normalized the level of HNE adducts
(Fig. 6a).
In the Sup fraction from both kidney and liver, the
level of HNE adducts did not increase in response to
HFD, while RGZ treatment resulted in a significant re-
duction below control levels (1.7- and 3.5-fold reduc-
tions for kidney and liver, respectively) (Fig. 6b, c). In
marked contrast to results with the Sup fraction (total
cell lysate), HFD induced a significant increase in HNE-
modified proteins in the Pellet fraction (detergent-resist-
ant membranes/lipid rafts) from both kidney and liver
(3.3- and 2.3-fold, respectively) (Fig. 6d, e). While RGZ
had no effect on the elevated levels of HNE adducts in
the kidney pellet fraction, RGZ treatment normalized
the HNE adduct levels in the liver pellet fraction (similar
to the result observed for RAGE levels in this fraction
(Fig. 5d)).
Discussion
We employed a rat model for metabolic syndrome that
fulfilled the established criteria for this syndrome, exhi-
biting three out of the five conditions required [2]:
Fig. 4 Quantitative immunoblotting of CML adducts in subcellular fractions from kidney and liver. The levels of the specific AGEs CML in response to
HFD in the absence and presence of RGZ were quantified in subcellular fractions (Sup and Pellet) from kidney and liver. Representative immunoblots
are shown in each panel along with the quantitation. Levels of CML in Sup fractions from (a) kidney and (b) liver; levels of CML in Pellet fractions from
(c) kidney and (d) liver. Sup = Triton X-100 soluble fraction; Pellet = Triton X-100 insoluble fraction, which enriches for detergent resistant membranes
(e.g., lipid rafts). Data are reported as means ± SEM for three independent experiments performed in duplicate. *P < 0.05
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increased blood pressure and increased levels of both
glucose and triglycerides. In addition, our rat model ex-
hibited other conditions often associated with metabolic
syndrome, including increased insulin resistance, kidney
dysfunction, and increases in indices of impaired liver
fat metabolism (i.e., increased levels of AST, hepatic total
lipids, hepatic triglycerides and hepatic total cholesterol).
Collectively, these data indicate that our rat model ad-
equately recapitulated the metabolic syndrome.
A comprehensive systems biology approach was
undertaken to examine the AROS axis during develop-
ment of metabolic syndrome and the response to treat-
ment with a PPARγ agonist (RGZ). A diagram depicting
the AROS axis and summarizing our results is shown in
Fig. 7. In response to HFD, virtually every measured par-
ameter of the AROS axis increased (upward red arrows).
Conversely, activation of PPARγ with RGZ resulted in
significant attenuation of nearly every measured param-
eter of the AROS axis, as well as attenuation of the de-
fining parameters of the metabolic syndrome itself
(downward green arrows).
Although many of the results from the current study are
consistent with previous reports using various models of
metabolic syndrome, this is one of the most comprehen-
sive studies using a single model to characterize both the
syndrome and its attenuation by a PPARγ agonist. Despite
the overall agreement of results from this study with pre-
vious ones, a few discrepancies should be mentioned.
The first issue to mention is body weight gain, which
did not occur in our model. Although weight gain has
been shown to be an early risk factor in the development
of non-alcoholic fatty liver disease (NAFLD) [44], it has
been reported that only 60% of metabolic syndrome pa-
tients actually gain weight [1]. Thus, this manifestation
is not necessarily required for development of metabolic
syndrome, even in humans, and also may not occur in
some rat models of metabolic syndrome. In a related
issue, treatment of diabetic patients with thiazolidine-
diones has also been reported to result in weight gain
[16], but this may also be an effect specific to humans.
Similar to our results with RGZ, in numerous animal
models with HFD alone or HFD in combination with
other diets, the thiazolidinidones did not induce add-
itional weight gain in rats with metabolic syndrome
[45–48].
Second, some recent evidence has been presented sup-
porting the hypothesis that steatosis (associated with
NAFLD) is a precursor to development of metabolic syn-
drome, at least in humans [36]. In our rat model, which
also exhibited several biochemical indicators of steatosis-
Fig. 5 Quantitative immunoblotting of RAGE expression levels in subcellular fractions from kidney and liver. The levels of RAGE expression in
response to HFD in the absence and presence of RGZ were quantified in subcellular fractions (Sup and Pellet) from kidney and liver. Representative
immunoblots are shown in each panel along with the quantitation. Levels of RAGE in Sup fractions from (a) kidney and (b) liver; levels of RAGE in
Pellet fractions from (c) kidney and (d) liver. Sup = Triton X-100 soluble fraction; Pellet = Triton X-100 insoluble fraction, which enriches for detergent
resistant membranes (e.g., lipid rafts). Data are reported as means ± SEM for three independent experiments performed in duplicate. *P < 0.05
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associated dyslipidemias (Additional file 2: Figure S2), no
histological evidence of frank steatosis was observed
(Additional file 1: Figure S1). Collectively, these data could
indicate that our model of metabolic syndrome, while
exhibiting functional features of abnormal fat metabolism,
has not yet reached an advanced stage in which morpho-
logically assessable manifestations have occurred in the
liver. Alternatively, steatosis may not be a necessary pre-
cursor for metabolic syndrome in rats.
Ultimately, differences in findings among the numer-
ous models employed may be accounted for by the vari-
ous differences in the individual models themselves,
including as examples: (i) differences between humans
and rodents, (ii) significantly different diet compositions,
(iii) different durations of both diet and drug treatments,
and (iv) age of the animals, among others.
Conclusions
Despite extensive efforts to completely understand the
metabolic syndrome, its exact pathogenic mechanism at
the molecular level remains incompletely defined, even
in the HFD rat model [4]. There is a strong consensus
that the AROS axis (i) plays a central role in induction
of the metabolic syndrome and (ii) is a target for the
counteracting effects of PPARγ agonists. In this study,
we applied a systems biology approach for comprehen-
sive evaluation of the multiple molecular modifications
taking place via stimulation of the AROS axis by HFD,
both without and with agonist potentiation of PPARγ ac-
tivity by RGZ. The results provide a more complete pic-
ture of the landscape of the AROS axis, and the study
serves as a proof-of-concept approach for evaluating
new drug candidates. Further characterization and
Fig. 6 Quantitative immunoblotting of HNE-protein adduct levels in plasma and subcellular fractions from kidney and liver. The levels of HNE-protein
adducts formed in response to HFD in the absence and presence of RGZ were quantified in plasma and subcellular fractions (Sup and Pellet) from
kidney and liver. Representative immunoblots are shown in each panel along with the quantitation. a Levels of plasma HNE; levels of HNE in Sup
fractions from (b) kidney and (c) liver; levels of HNE in Pellet fractions from d) kidney and (e) liver. Sup = Triton X-100 soluble fraction; Pellet = Triton
X-100 insoluble fraction, which enriches for detergent resistant membranes (e.g., lipid rafts). Data are reported as means ± SEM for three independent
experiments performed in duplicate. * P < 0.05; **P < 0.01; *** P < 0.001
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Fig. 7 Diagram depicting the AROS axis and summarizing our results. The metabolic syndrome is probably generated through the activation of
the AROS axis [8]. Reactive sugar aldehydes form adducts with proteins (AGEs) which then bind to their specific receptor (RAGE, localized in a
specialized membrane compartment, the lipid raft), initiating the RAGE signalling cascade. As a result, enzymes generating reactive oxygen species
(ROS) are activated, which in turn activates NF-kB translocation from cytosol to nucleus, ultimately altering expression of numerous genes, including
upregulation of pro-inflammatory cytokines (TNF-α, IL-6). The resulting inflamation, in turn, is responsible for additional tissue oxidative stress (AOPP
production) [49], lipoxidation and HNE production [9–13], all contributing to a further elevation and perpetuation of both molecular/cellular damage
and the inflammatory response [50]. Activation of PPARγ binding by RGZ also leads to altered expression of numerous genes, including upregulation
of a soluble isoform of RAGE able to bind extracellular AGEs for clearance from the plasma [51], thereby attenuating (at least in part) the AROS axis.
Summary of results from this study: (i) upward red arrows = increased levels of the indicated measured parameters in response to HFD; (ii) downward
green arrows = decreased levels of the indicated measured parameters in response to RGZ
Cannizzaro et al. Nutrition & Metabolism  (2017) 14:5 Page 11 of 13
identification of the glycated and lipoxidated proteins
using this strategy should provide deeper insights into
their functional role in the complex molecular mecha-
nisms involved in metabolic syndrome.
Additional files
Additional file 1: Figure S1. Representative images of liver and kidney
histological sections. No significant difference for steatosis or fibrosis was
observed in liver (upper row) between the groups. A) CTR, (B) HFD, (C)
RGZ; no morphological evidence of damage, such as glomerulosclerosis,
interstitial inflammatory cell infiltrates, tubular dilatation and/or atrophy
and interstitial fibrosis, was detected in kidney (lower row): (D) CTR, (E)
HFD, (F) RGZ. Images were acquired with NanoZoomer-XR C12000 series,
scale bars = 250 μm. (JPG 82 kb)
Additional file 2: Figure S2. Biochemical surrogate indices of impaired
liver fat metabolism. In response to HFD, increased levels of surrogate
indices of steatosis/dyslipidemia were observed, including: A) aspartate
aminotransferase (AST), D) hepatic triglycerides, E) hepatic total
cholesterol and F) hepatic total lipids, but not B) alanine transaminase
(ALT) or C) plasma total cholesterol. Moreover, the increase in the levels
of hepatic triglycerides (D) and hepatic total cholesterol (E) were
significantly reduced by RGZ treatment, but RGZ did not significantly
affect the increase in the levels of AST (A) or hepatic total lipids (F). Data
are mean ± SEM * P < 0.05; **P < 0.01; *** P < 0.001. (JPG 45 kb)
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